Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will be announcing its earnings results after the market closes on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.76) per share for the quarter.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.19. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.46 million. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The business’s revenue was down 24.5% compared to the same quarter last year. During the same period last year, the company earned ($0.46) EPS. On average, analysts expect Tetraphase Pharmaceuticals to post $-2.74 EPS for the current fiscal year and $-2.18 EPS for the next fiscal year.

Tetraphase Pharmaceuticals, Inc. (TTPH) opened at 6.90 on Wednesday. The company’s market cap is $261.90 million. Tetraphase Pharmaceuticals, Inc. has a 12 month low of $3.11 and a 12 month high of $9.93. The firm has a 50-day moving average price of $7.47 and a 200 day moving average price of $6.81.

A number of equities research analysts have commented on TTPH shares. BMO Capital Markets restated a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. HC Wainwright started coverage on Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $8.45.

ILLEGAL ACTIVITY NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) to Release Quarterly Earnings on Wednesday” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/26/tetraphase-pharmaceuticals-inc-ttph-to-release-quarterly-earnings-on-wednesday.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.